Daniel Pollyea, MD, MS, University of Colorado Denver

Dan Pollyea, MD, MS, he University of Colorado School of Medicine

Dan Pollyea, MD, MS, discusses the mechanism of action for the menin inhibitor revumenib in KMT2A-rearranged relapsed/refractory acute myeloid leukemia.

Final Thoughts on New Developments and Emerging Agents

Harry P. Erba, MD, PhD, Duke Cancer Institute;Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ;Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ;Daniel Pollyea, MD, MS, University of Colorado Denver;Vinod Pullarkat, MD, City of Hope Medical Center

September 9th 2021

Panelists conclude by reviewing possible advancements on the horizon in AML such as the potential emergence of Menin inhibitors and bispecific T-cell engagers as well as improved methods for predicting response and preventing relapse.

Treatment Approaches for TP53-Mutated AML

Harry P. Erba, MD, PhD, Duke Cancer Institute;Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ;Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ;Daniel Pollyea, MD, MS, University of Colorado Denver;Vinod Pullarkat, MD, City of Hope Medical Center

September 9th 2021

Key opinion leaders in hematology oncology share insights into the challenges associated with treating patients with TP53-mutated AML and highlight the recent FDA breakthrough designation of eprenetapopt.

Evolving Treatment Approaches Pre- and Post-Transplant

Harry P. Erba, MD, PhD, Duke Cancer Institute;Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ;Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ;Daniel Pollyea, MD, MS, University of Colorado Denver;Vinod Pullarkat, MD, City of Hope Medical Center

September 2nd 2021

Vinod Pullarkat, MD, leads a detailed discussion on evolving treatment approaches using MRD pretransplant, and panelists consider recent therapeutic advances for the post-transplant setting.

5-Year Follow-up Data on CPX-351 for AML

Harry P. Erba, MD, PhD, Duke Cancer Institute;Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ;Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ;Daniel Pollyea, MD, MS, University of Colorado Denver;Vinod Pullarkat, MD, City of Hope Medical Center

September 2nd 2021

A panel of specialists in hematology oncology review the 5-year follow-up data on the use of CPX-351 for adults and pediatric patients with acute myeloid leukemia.

The Role of Allogeneic Stem Cell Transplant in AML

Harry P. Erba, MD, PhD, Duke Cancer Institute;Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ;Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ;Daniel Pollyea, MD, MS, University of Colorado Denver;Vinod Pullarkat, MD, City of Hope Medical Center

August 26th 2021

Dan Pollyea, MD, MS provides a high-level overview of the role of allogeneic stem cell transplant at first remission based on risk stratification, highlighting how to select patients for transplant.

Approaches to Managing Toxicity of Venetoclax

Harry P. Erba, MD, PhD, Duke Cancer Institute;Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ;Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ;Daniel Pollyea, MD, MS, University of Colorado Denver;Vinod Pullarkat, MD, City of Hope Medical Center

August 26th 2021

Courtney DiNardo, MD emphasizes the importance of understanding the risk of tumor lysis syndrome, monitoring for drug-drug interactions, and performing a bone marrow biopsy at the end of cycle 1 when treating AML with venetoclax.

The Role of Venetoclax for Treatment of AML

Harry P. Erba, MD, PhD, Duke University School of Medicine;Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ;Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ;Daniel Pollyea, MD, MS, University of Colorado Denver;Vinod Pullarkat, MD, City of Hope Medical Center

August 19th 2021

Renowned experts in hematology-oncology provide insight into the practical implications of treating acute myeloid leukemia with the current standard-of-care regimen using venetoclax.

Venetoclax Combination Therapy for IDH-mutated AML

Harry P. Erba, MD, PhD, Duke Cancer Institute;Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ;Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ;Daniel Pollyea, MD, MS, University of Colorado Denver;Vinod Pullarkat, MD, City of Hope Medical Center

August 19th 2021

Key opinion leader in the management of acute myeloid leukemia, Harry Erba, MD PhD, builds a conversation on the use of venetoclax as a part of combination therapy in patients with IDH mutations.

Combination Approaches Targeting FLT3 and IDH Mutations

Harry P. Erba, MD, PhD, Duke Cancer Institute;Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ;Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ;Daniel Pollyea, MD, MS, University of Colorado Denver;Vinod Pullarkat, MD, City of Hope Medical Center

August 12th 2021

Expert hematologist-oncologists share insights into clinical trials studying how to best combine or sequence FLT3 and IDH inhibitors in patients with both mutations.

Toxicities Associated With IDH Inhibitors

Harry P. Erba, MD, PhD, Duke Cancer Institute;Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ;Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ;Daniel Pollyea, MD, MS, University of Colorado Denver;Vinod Pullarkat, MD, City of Hope Medical Center

August 12th 2021

A panel of key opinion leaders in acute myeloid leukemia reflects on the importance of considering the toxicity profiles of IDH inhibitors and emphasizes the challenges of diagnosing differentiation syndrome.

The Role of IDH Inhibitors for Treatment of AML

Harry P. Erba, MD, PhD, Duke Cancer Institute;Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ;Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ;Daniel Pollyea, MD, MS, University of Colorado Denver;Vinod Pullarkat, MD, City of Hope Medical Center

August 5th 2021

Harry Erba, MD, PhD; Courtney DiNardo, MD; and Dan Pollyea, MD, MS, discuss the role of the IDH inhibitors ivosidenib and enasidenib as single-agent or combination therapy in patients with acute myeloid leukemia (AML).

Combining and Sequencing FLT3 Inhibitors in AML

Harry P. Erba, MD, PhD, Duke Cancer Institute;Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ;Mark J. Levis, MD, PhD, Johns Hopkins University;Daniel Pollyea, MD, MS, University of Colorado Denver;Vinod Pullarkat, MD, City of Hope Medical Center

August 5th 2021

Harry Erba, MD, PhD; Courtney DiNardo, MD; Mark Levis, MD, PhD; and Vinod Pullarkat, MD, review factors to consider when using combining and/or sequencing first- or second-generation FLT3 inhibitors for patients with acute myeloid leukemia (AML).

Second-Generation FLT3 Inhibitors for Acute Myeloid Leukemia

Harry P. Erba, MD, PhD, Duke Cancer Institute;Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ;Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ;Daniel Pollyea, MD, MS, University of Colorado Denver;Vinod Pullarkat, MD, City of Hope Medical Center

July 29th 2021

A panel of thought leaders in AML examines single-agent and combination-based approaches using the second-generation FLT3 inhibitors gilteritinib, quizartinib, and crenolanib.

The Role of FLT3 Inhibitors for Treatment of AML

Harry P. Erba, MD, PhD, Duke Cancer Institute;Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ;Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ;Daniel Pollyea, MD, MS, University of Colorado Denver;Vinod Pullarkat, MD, City of Hope Medical Center

July 29th 2021

Experts in hematologic malignancies provide key insights into the use of FLT3 inhibitors and discuss whether it is possible to predict patients who may benefit from midostaurin + chemotherapy.

Molecular Testing Turnaround Time and Treatment Delay

Harry P. Erba, MD, PhD, Duke Cancer Institute;Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ;Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ;Daniel Pollyea, MD, MS, University of Colorado Denver;Vinod Pullarkat, MD, City of Hope Medical Center

July 22nd 2021

Key opinion leaders in acute myeloid leukemia reflect on challenges associated with molecular testing by commenting on potential treatment delay from the long turnaround time (TAT) of next-generation sequencing.

Molecular Testing for Acute Myeloid Leukemia

Harry P. Erba, MD, PhD, Duke Cancer Institute;Daniel Pollyea, MD, MS, University of Colorado Denver;Vinod Pullarkat, MD, City of Hope Medical Center;Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ;Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center

July 22nd 2021

Mark Levis, MD, PhD, leads a panel of experts in a discussion on factors to consider when ordering molecular testing for newly diagnosed and relapsed/refractory acute myeloid leukemia.